Regulation of Drugs for Early Alzheimer’s Disease

In this exchange, the authors argue that further loosening FDA approval standards for early-stage Alzheimer’s drugs risks encouraging development of ineffective medications. The FDA officials reply their proposed accelerated approval framework for disease-modifying therapies in very early Alzheimer’s is distinct from symptom-based approvals and includes appropriate safeguards.